Resumo

TAMAYO-ALONSO, Pilar et al. Update on radiactive iodine treatment of differentiated thyroid cancer. Rev. ORL [online]. 2021, vol.12, n.4, pp.371-380.  Epub 02-Maio-2022. ISSN 2444-7986.  https://dx.doi.org/10.14201/orl.25746.

Radioiodine (RAI) therapy of differentiated thyroid carcinoma (DTC) has been used for more than seventy years. However, there is no consensus regarding indications, doses, procedures, and other aspects related to the clinical care of the patients considered for 131I therapy. Furthermore, in recent years the need for additional therapy with RAI in patients with DTC after surgery has been questioned, as has been done by the 2015 American Thyroid Association (ATA) guidelines. Guidelines that were not endorsed by the European and American Nuclear Medicine Societies (EANM and SNMIM, respectively), which led to meetings (Martinique Encounters) between EANM, SNMIM and the American (ATA) and European Thyroid (ETA) Societies. Two meetings have been held, in 2018 and 2019, in which some principles were established (Principles of Martinique). These principles and the results of the most recent publications, regarding the potential of RAI therapy in patients with DTC, will be the object of development in this work to carry out an update on the treatment of DTC with RAI.

Palavras-chave : differentiated thyroid cancer; radioactive iodine treatment; I-131; radioiodine refractory thyroid cancer; adjuvant therapy.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )